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Introduction
Separation of graft-versus-leukemia from graft-versushost immune reactions remains the major challenge in allogeneic hematopoietic stem-cell transplantation (HSCT). 1 Both effects are mainly mediated by T cells that are contained in donor-derived stem-cell grafts and lymphocyte products with a very broad repertoire of allospecificities. 2 Therefore, refined in vitro strategies have been developed that selectively deplete graft-versus-hostreactive (i.e. alloreactive) donor T cells while sparing beneficial reactivity of T cells to infectious agents and leukemia. 3 Although several of these approaches have already been demonstrated to be feasible and produce significant reductions of graft-versus-host disease (GvHD) in clinical trials, [4] [5] [6] [7] [8] selective depletion of alloreactive T cells is still a complex technical approach and requires the in vitro culture of donor T cells for several days.
A less complex, culture-independent approach for GvHD prophylaxis would be to eliminate naïve T cells from the allograft, because they should contain most alloreactive precursors due to the enormous diversity of the naive T-cell receptor (TCR) repertoire. 9 Studies in mice have established this concept by demonstrating a much higher rate of GvHD if naive T cells compared to memory T cells of unprimed animals were adoptively transferred into allogeneic recipients. [10] [11] [12] In vitro experiments with human T cells confirmed that the CD62L pos subset containing naïve and central memory T cells showed stronger alloresponses than the CD62L neg effector memory counterpart. 13 These data, however, raise important questions. First, which marker(s) of T-cell differentiation should be used clinically for depleting naïve T cells with the aim of minimizing alloreactive precursors in human allografts? Second, is the superior alloresponse of naïve precursors similar in CD4 and CD8 T-cell subsets? Lastly, will residual memory T cells still mediate reactivity to leukemia? Naïve T cells have the phenotype CD45RA pos CD45RO neg CCR7 pos CD62L pos ; CCR7 and CD62L are also expressed on central memory T cells. 14, 15 We, therefore, decided to investigate in vitro alloreactivity of CD4 and CD8 T-cell subsets which were enriched for naïve (i.e. CD45RA pos and CD45RO neg ) as well as for naïve and central memory T cells (i.e. CCR7 pos and CD62L pos ) by flow cytometric cell sorting. The counterpart fractions mainly containing memory T cells as well as entire CD4 and CD8 T cells were also included in the experiments. Because alloreactivity is very complex and can be directed to a very diverse panel of major and minor histocompatibility antigens mismatched between donor and recipient, we chose single non-self-HLA (allo-HLA) molecules as surrogate alloantigens. To detect pure alloreactive T-cell responses against an individual HLA mismatch allele and to minimize the interference by other T-cell specificities, HLAdeficient K562 cells were applied as standard recipient cells and were transfected with single HLA class I (-A/-B/-C) or class II (-DR/-DQ) molecules before use.
Design and Methods

Primary cells and cell lines
This study was approved by the local Ethics Committee and was performed according to the Declaration of Helsinki. Healthy peripheral blood mononuclear cell (PBMC) donors were selected based on their HLA type (Online Supplementary Table S1 ). PBMC were isolated from buffy coats by Ficoll separation. Primary AML blasts were separated by Ficoll centrifugation from leukapheresis products of patients with a white blood cell count greater than 10 5 /μL. The K562 cell clone transfected with HLA-A*02:01 cDNA has been previously described. 16 
Cell sorting and allostimulation of CD8 and CD4 T-cell subsets in vitro
Cryopreserved PBMC were thawed and stained with fluorochrome-conjugated monoclonal antibodies for CD3 and CD8 or CD4, in combination with those for CD45RA, CD45RO, CCR7, or CD62L (Beckman Coulter, Brea, CA; BD Biosciences, San Jose, CA, USA; R&D Systems, Minneapolis, MN, USA). After washing, cells were sorted on a BD FACSAria cell sorter (BD Biosciences) into the indicated T-cell subsets ( Figure 1C ). Allogeneic mixed lymphocyte reactions (MLR) were performed at 37°C in AIM-V medium (GIBCO-BRL, Carlsbad, CA, USA) supplemented with 10% heat-inactivated human serum. At day 0 (d0), 5¥10 5 sorted CD8 or CD4 T cells were stimulated with 5¥10 4 lethally irradiated mismatched K562-HLA transfectant cells in 48-well plates. Irradiated (35 Gy) autologous PBMC (5¥10 5 /well) were added as feeder cells. MLR responder populations were re-stimulated weekly with irradiated K562-HLA cells at a responder:stimulator ratio of 10:1. Cultures contained 10 ng/mL human interleukin (hIL)-7, 1 ng/mL hIL-12, and 5 ng/mL hIL-15 (all from Miltenyi Biotec, Bergisch-Gladbach, Germany) during the first week. From d7 onwards, IL-12 was omitted, and hIL-2 was added at 100 IU/mL (ProleukinTM; Novartis, Nürnberg, Germany).
For the generation of leukemia-reactive CD8 T-cell lines, 5¥10 5 cells of sorted CD8 T-cell subsets from healthy donors were stimulated in allogeneic mixed lymphocyte-leukemia cultures (MLLC) with 5¥10 5 irradiated (35 Gy) HLA class I-matched primary acute myeloid leukemia (AML) blasts. Irradiated autologous PBMC (5¥10 5 /well) of donor origin were added as feeder cells. MLLC were supplemented with the same cytokines as described for the MLR. Additionally, 10 ng/mL hIL-21 (Biomol, Hamburg, Germany) was added to improve in vitro priming of leukemia-reactive T-cell precursors. 17 Cultures were re-stimulated weekly with irradiated AML blasts at a responder:stimulator ratio of 1:1.
T-cell expansion was measured by counting viable cells every week with trypan blue staining. Statistical analysis between different experimental arms was performed with SPSS15.0 software. Wilcoxon's signed-rank test was used to calculate P values. 
Interferon-γ enzyme-linked immunosorbent spot assay
Twenty-hour interferon-γ (IFN-γ) enzyme-linked immunosorbent spot (ELISpot) assays were performed as described previously. 18 Chromium-release assays with an effector-to-target (E/T) incubation of 5 h were conducted as previously described. 19 Data shown data are means ± SD of duplicate experiments.
Results
Measuring alloreactivity of CD8 T-cell subsets to single HLA mismatch alleles
We separated CD8 T cells from PBMC of healthy donors by flow cytometric sorting according to the strong or absent expression of CD45RA, CD45RO, CD62L, or CCR7, respectively ( Figure 1 ). Eight different CD8 T-cell subsets with a median purity of 98.7 (77.1-100) % (n=56) were obtained and were analyzed for alloreactivity to single HLA-A, HLA-B, and HLA-C mismatch alleles by allogeneic MLR in vitro. Sorted total CD8 T cells were also included in the MLR experiments. For in vitro stimulation against allo-HLA, we used HLA-deficient K562 cells expressing single HLA molecules (K562-HLA) after transfection. MLR populations were regularly screened for allo-HLA-reactive CD8 T cells by IFN-γ ELISpot assay on d12 of cultures. We detected HLA-mismatch reactivity primarily in MLR that were initiated with CD8 subsets enriched for naïve T cells ( Figure 2A ). Recognition was clearly restricted to the allo-HLA mismatch allele used during primary in vitro stimulation. This was demonstrated by including parental K562 cells and K562 transfectant cells expressing third-party HLA class I alleles as control targets in all screening assays. In addition, allorecognition could be regularly blocked by monoclonal antibodies binding to the allo-HLA stimulator allele ( Figure 2A ).
Superior allogeneic HLA reactivity in subsets enriched for naïve compared to memory CD8 T cells
We next used the MLR-ELISpot test system to screen subsets enriched for naïve or memory CD8 T cells for reactivity to single HLA-A/-B/-C mismatch alleles in six different donors (for HLA types see Online Supplementary  Table S1 ). We observed that much higher numbers of HLA mismatch-reactive CD8 T cells were derived from the Figure S2A ,B). In contrast, the CD62L neg and CCR7 neg counterparts showed significantly lower cell expansion (median d21: 3.6¥10 7 and 1.7¥10 7 cells; P=0.015 and P=0.037). Similar differences in alloproliferation were not found for CD45RA and CD45RO subsets. We also analyzed the expression of T-cell differentiation markers in all MLR populations on d14 of culture by flow cytometry. As expected, subsets enriched for naïve CD8 T cells retained expression of early differentiation markers in a higher proportion of MLR responders compared to memory counterparts (data not shown).
Stronger leukemia reactivity in CCR7 pos compared to CCR7 neg CD8 T cells
Because the CCR7 pos CD8 T-cell subset of healthy individuals contained most allo-HLA-reactive effector cells (Figure 2 ), depletion of this compartment from entire donor lymphocytes would potentially reduce graft-versushost-reactivity of HLA-mismatched allografts. However, elimination of donor CCR7 pos CD8 T cells may also influence T-cell reactivity to leukemia cells restricted by HLA alleles matched between the donor and leukemia patient. We, therefore, investigated sorted CCR7 pos and CCR7 neg CD8 T cells of three healthy donors for reactivity to primary AML blasts in donor-patient pairs with complete HLA match by allogeneic MLLC. In parallel experiments, reactivity of both subsets to K562 cells expressing a single HLA class I mismatch allele was also analyzed by MLR. We observed high numbers of AML-reactive CD8 T cells in CCR7 pos -derived MLLC, both in HLA-matched sibling and unrelated donors ( Figure 3A ). Responding CD8 T cells showed cytolytic activity against AML blasts, but did not lyse natural killer target K562. A lower level of lysis was observed against patient-derived B-lymphoblastoid cell lines. In contrast, we did not detect AML-reactive CD8 T cells in CCR7 neg -derived MLLC. As expected from our previous data, allo-HLA reactivity mainly resided in CCR7 pos fractions ( Figure 3B ). Similar MLLC results were obtained if CD45RO was used for sorting naïve and memory CD8 T cells (data not shown).
Separation of allogeneic HLA reactivity in subsets enriched for naïve and memory CD4 T cells CD4 T cells of six healthy donors were sorted into subsets enriched for naïve or memory T cells using a strategy analogous to that described for CD8 T cells (Figure 1) , with a median purity of 99.8 (82.8-100) % for all fractions (n=48). The subsets were stimulated weekly in MLR with K562 cells expressing single HLA-DR/-DQ mismatch alleles in nine donor/allo-HLA combinations (Online Supplementary Table S1 ). Again, allorecognition was measured by IFN-γ ELISpot assay in the second week of cultures (d12). We observed that the numbers of allo-HLA class II reactive T cells were usually higher in subsets enriched for naïve T cells than in those enriched for the memory counterparts ( Figure 4B-C) . Statistical significance was found for the CD62L (P=0.008) and CD45RA (P=0.011) subsets. The median level of mismatch reactivity was clearly higher for the used HLA-DR than for the HLA-DQ allele (601 versus 93 SFC per 10 4 MLR responders for all naïve CD4 subsets). In all experiments, allo-HLA class II reactivity could be blocked by monoclonal antibodies binding to the class II molecule used for primary in vitro stimulation ( Figure 4A ). Furthermore, significant alloresponses to parental K562 cells as well as to transfectants carrying third-party HLA alleles were not observed, again demonstrating the specificity of the MLR/K562-HLA screening approach. As for the CD8 experiments, alloreactivity of MLR cultures derived from memory-enriched CD4 T-cell subsets was substantially lower than that of total CD4 T cells. entire CD4 T cells. In addition to IFN-γ, CD4 MLR responder populations of individual donors secreted low levels of IL-4 and tumor necrosis factor-α, with a tendency of stronger production in MLR derived from naïve-enriched subsets (data not shown). The proliferation of MLR cultures from CD4 T-cell subsets toward single HLA class II mismatch alleles was overall stronger (Online Supplementary Figure S3 ) than that of cultures from similar allo-HLA class I/CD8 experiments. This was particularly detectable for all memory fractions. Significant differences in alloproliferation between MLR cultures derived from subsets enriched for naïve or memory CD4 T cells were not observed. Furthermore, flow cytometric analysis of MLR on d14 showed that subsets enriched for naïve CD4 T cells retained the expression of early differentiation markers in a higher proportion of MLR responders compared to subsets enriched for memory counterparts (data not shown). In order to determine the distribution of naturally occurring Treg to memory versus naïve CD4 T-cell subsets, CD45RA pos and CD45RA neg fractions from five donors were co-stained for CD25 Finally, we combined the allo-HLA recognition data of CD8 and CD4 T cells (Figures 2 and 4) to identify which subset marker would allow for most efficient separation of alloreactivity in entire T cells. As shown in Online Supplementary Figure S4A, Figure S4B) . The median reductions in alloproliferation between total CD4/CD8 T cells and memory fractions were 0.7-fold for CD45RA neg (P=0.31), 1. 
Discussion
Here we introduce a rapid screening approach to detect T-cell reactivity of donors to single HLA mismatch alleles. It uses a combination of short-term MLR with a sensitive IFN-γ ELISpot readout system. The main components are HLA-deficient K562 cells that are transfected with 'offthe-shelf' HLA class I and II molecules, resulting in stable or transient HLA expression depending on the favored transfection method. By in vitro stimulation of T cells of healthy individuals with single HLA mismatch alleles, we observed that the number of allo-HLA-reactive IFN-γ-producing T cells is usually higher in subsets enriched for naïve cells compared to memory T cells. This finding was very consistent, regardless of whether CD8 or CD4 T cells were analyzed. We hereby confirm a previous report showing stronger alloreactivity in human CD62L pos compared to CD62L neg T-cell subsets in vitro. 13 This earlier study used a mixture of several HLA-mismatched B-lymphoblastoid cell lines as MLR stimulator cells, which has the limitation compared to the K562-HLA test system that detected alloreactivity cannot be attributed to single HLA alleles. Furthermore, if residual HLA molecules are matched between donor T cells and recipient B-lymphoblastoid cell lines, alloreactivity interferes with T-cell responses against recipient antigens presented by shared HLA. Such responses (e.g. against Epstein Barr virus) are most likely not equally distributed between donor-derived naïve and memory T cells.
It has long been debated which combination of differentiation markers spans the naïve T-cell pool most precisely. 15 We used the common definition of naïve T cells by CD45 isoforms (i.e. RA pos , RO neg ) and also included CCR7 and CD62L comprising naïve and central memory T cells in the analysis. 14 We found that depletion of central memory T cells additionally to naïve precursors (as represented by CD62L neg or CCR7 neg subsets) did not lead to significantly decreased allo-HLA responses compared to central Of all subsets, only data for CD45RA-sorted naïve and memory populations were significantly different (P<0.05) for both CD8 and CD4 T cells. In addition, the number of allo-HLA-reactive effector cells was reduced in median by 7.2-fold and 16.6-fold in CD45RA neg memory CD8 and CD4 T cells compared to in entire CD8 and CD4 T cells, respectively. We also observed that a higher fraction of naturally occurring Treg resided in the CD45RA neg CD4 subset than in the CD45RA pos one and might have contributed to lower alloreactivity mediated by memory CD4 T-cell fractions. The proliferative response of sorted memory T-cell subsets to allo-HLA was more variably reduced (CD8) or equivalent (CD4) than the IFN-γ response when compared to naïve T-cell subsets. This finding requires further consideration, since proliferation is a much more complex feature of alloreactivity than IFN-γ secretion. We, therefore, investigated whether the lack of correlation between d21 alloproliferation and d12 allorecognition (IFN-γ ELISpot) data might be a result of the prolonged culture period that promoted a switch from naïve to memory T cells in MLR. However, we did not find significant differences in alloproliferation between naïve and memory T-cell subsets during the first week of MLR when using cell counting and CFSE staining as readout assays (data not shown).
Our data also suggest that depletion of naïve T cells will 14, 15 We and others have reported that cytotoxic T lymphocyte-mediated reactivity to leukemia cells mainly derives from naïve CD8 T cells in healthy unprimed individuals 19, [21] [22] [23] and that such cytotoxic T lymphocytes target polymorphic minor histocompatibility antigens (mHag) and non-polymorphic leukemia-associated antigens (LAA). 21, 22, 24 These findings are further supported by HLA-peptide multimer data in ex vivo PBMC showing most precursors of LAA-reactive CD8 T cells in the naïve subset of healthy individuals. 25 In contrast, other groups detected HLA-peptide multimer binding leukemiareactive CD8 T cells also in the antigen-experienced memory pool. This was demonstrated for LAA specificities in healthy donors 26 as well as for mHag specificities in donors with a history of alloantigen priming in vivo (e.g. multiparous females, 27 cord blood grafts 28 ). Ideally, this would suggest memory T cells from donors previously primed against hematopoietically expressed mHag and LAA by natural immunization or vaccination should be used for transplantation.
Although the concept of 'memory T-cell therapy' is promising in terms of the expected lower GvHD potential, we detected single donors who had strong alloreactivity in individual memory subsets. Because memory T cells have the capability of rapid expansion upon secondary antigen challenge, 29 the formation of alloreactive memory T cells may have serious consequences in terms of GvHD. Presensitization would be a particular problem if pathogenspecific T cells with cross-reactivity to alloantigens are triggered by an encounter with infectious agents. [30] [31] [32] We propose the use of the K562-HLA-based MLR approach for the screening of donor T-cell reactivity to individual HLA class I and II mismatch alleles in situations in which a donor with full HLA match is lacking. Such donor-patient HLA disparities, particularly at the A/B/C/DR loci, increase the risk of graft rejection and severe GvHD, and may even decrease survival after allogeneic HSCT. [33] [34] [35] [36] The approach might help to select a HLAmismatched donor (e.g. in haploidentical HSCT) with the lowest level of reactivity against non-shared recipient HLA antigens. With the test system, we detected much stronger allorecognition of HLA-A/-B/-C/-DR versus HLA-DQ alleles, which is consistent with the clinical observation that HLA-DQ mismatches are better tolerated and do not adversely affect the outcome of allogeneic HSCT. 35, 36 In conclusion, allo-HLA mismatch reactivity was preferentially derived from subsets enriched for naïve compared to memory T cells in most healthy individuals. This was demonstrated by using single alleles from all HLA-A/-B/-C/-DR/-DQ loci currently included in donorpatient typing for allogeneic HSCT. We also observed that in vitro strategies for depleting naïve T cells could use several major differentiation markers expressed by naïve T cells (i.e. CD45RA to develop a suitable sorting strategy. In our hands, the most efficient results for entire T cells were obtained with CD45RA. We also demonstrated the major limitation of the approach, which is the concurrent impairment of Tcell responses against leukemia. This problem might be addressed by using donor allografts which contain leukemia-reactive T cells in the memory compartment due to previous priming against mHag and LAA during natural immunity or vaccination. Alternatively, memory T cells could be replenished with leukemia-reactive T cells previously isolated from the naïve T-cell subset of donors by primary in vitro stimulation. 19, 22, 23 The establishment of a Good Manufacturing Practice procedure for depleting naïve T cells (or selecting memory T cells) in vitro appears feasible. This would pave the way for clinical trials that investigate whether depletion of naïve T cells from donor-derived stem-cell grafts or lymphocyte products can indeed reduce GvHD in HSCT patients. Most suitable study populations are HLA-mismatched patients at high risk of GvHD and low risk of leukemia relapse, as well as patients with diseases other than leukemia. 
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